Making a therapeutic that contains biological components is just the start of creating a medicine. Then, biopharmaceutical companies must capture that drug and ensure that it’s free of contamination.

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

FUJIFILM Biotechnologies introduces ShunzymeX precision purification technology for downstream processing of complex biologics: Teessid, United Kingdom Thursday, March 5, 2026, 16 ...

Creative Biolabs announces upgraded downstream services designed to bridge the gap between raw antibody expression and advanced preclinical development. SHIRLEY, NY ...

The vast structural diversity of proteins is responsible for their functional versatility, but also makes their expression and purification a demanding task. Tagging proteins with affinity tags can ...